Missouri’s Hemp Ban No Longer Has a Single Deadline, and the Lawsuit Over It Is Still Open

House Bill 2641, which Governor Mike Kehoe signed on April 23, 2026, creates the Intoxicating Cannabinoid Control Act and treats hemp-derived cannabinoid products as marijuana under Missouri’s constitutional framework. Only entities licensed by the Department of Health and Senior Services may cultivate, produce, manufacture, test, transport, or sell them.

The effective date is the part patients need to understand. The Missouri House summary of the truly agreed bill states that the covered provisions take effect November 12, 2026, or, if Congress delays the effective date of federal hemp restrictions, that they apply only during any period in which the federal restrictions prohibit those products. Congress did delay part of that schedule on September 2, 2026. The practical consequence is that different product categories now reach their Missouri deadline on different dates, and the statute does not spell that out product by product.

Missouri is one of the few states where hemp THC seltzers moved into ordinary grocery stores, bars, and gas stations at scale. A large number of people who would never describe themselves as cannabis patients have been using a labeled, low-dose beverage for sleep, anxiety, or as a substitute for alcohol. Those people will be affected by a legal change they are not tracking.

When a product category disappears on a date nobody can state confidently, the substitutions happen in the dark. Some buyers move to a licensed dispensary, where products are stronger and priced differently. Some move to mail order from states with looser rules. Some go back to alcohol. Each of those is a clinically relevant change, and none of them will be volunteered at a visit unless somebody asks.

The Governor’s office announced the signing on April 23, 2026, describing House Bill 2641 as creating provisions relating to cannabis and establishing the Intoxicating Cannabinoid Control Act. The law aligns Missouri’s hemp definition with the federal standard and requires entities that are not licensed to stop manufacturing hemp-derived cannabinoid products.

Under the Missouri House summary of the truly agreed and finally passed bill, only entities licensed by the Department of Health and Senior Services may cultivate, produce, manufacture, test, transport, and sell the covered products. Unlicensed sellers may not use the word dispensary in a business name, a violation carried as a class D felony with a five thousand dollar fine per transaction.

The statute also restricts licensed dispensaries from creating consumer records without written consent and from denying service to a customer who declines to provide identifying information, with a five hundred dollar penalty per occurrence. That privacy provision has nothing to do with hemp and is easy to miss inside a bill known for the ban.

The Missouri House summary states that the covered provisions become effective on November 12, 2026, or, if Congress delays the effective date of federal hemp restrictions, that the provisions apply only during any period in which the federal restrictions prohibit those products.

That clause was written when the federal schedule looked like a single date. Section 781 of Public Law 119-37, signed November 12, 2025, was set to take effect on November 12, 2026. Congress then changed the shape of the deadline rather than the deadline itself.

H.R. 6500, the continuing appropriations act signed September 2, 2026, moved most section 781 provisions to December 11, 2026, while leaving the exclusion for cannabinoids that a cannabis plant cannot naturally produce on the original November 12, 2026 schedule. Federal law now prohibits one set of products a month before the other.

Read the state clause against the federal act and the practical result is two groups rather than one. Products caught by the federal exclusion for cannabinoids a cannabis plant cannot naturally produce, which is where converted delta-8, hexahydrocannabinol, and tetrahydrocannabiphorol sit, reach a federal prohibition on November 12, 2026. Products reached only by the federal quantitative limits, which is where most naturally derived low-dose delta-9 beverages sit, do not reach one until December 11, 2026.

Because Missouri’s provisions apply during the period in which the federal restrictions prohibit the products, the state deadline for those two groups is not the same day. That is the reading the statutory language supports, and it matches how Missouri reporting has described the beverage question since the federal measure moved.

What makes this uncomfortable rather than merely technical is that the Missouri Department of Health and Senior Services cannabis regulation page carries no HB 2641 implementation notice as of September 14, 2026. Its posted announcements cover microbusiness licensing, a curbside pickup rule amendment, fingerprinting, and agent identification. Retailers, buyers, and clinicians are reading the statute without agency guidance on top of it.

On July 16, 2026, a hemp industry coalition filed Mohemp Trade Association v. Kehoe, No. 2:26-cv-04170, in the U.S. District Court for the Western District of Missouri, Central Division. The plaintiffs are the Mohemp Trade Association, Lifted Liquids, Inc., and MNG 2005, Inc. The named defendants include Governor Mike Kehoe, Attorney General Catherine Hanaway, and a state health official. The case is assigned to District Judge M. Douglas Harpool and the docketed cause is the constitutionality of state statutes under 28 U.S.C. section 2201.

The defendants moved to dismiss on August 4, 2026, and the docket reflects routine scheduling activity after that. No order enjoining the statute appears, and the case has not been terminated.

The plaintiffs’ central claim is that the definitions of hemp and marijuana in the law conflict with one another closely enough that businesses, police, and prosecutors cannot tell which products are covered or when. The effective-date split described above is a fair illustration of the problem they are describing, whether or not a court ultimately agrees that it rises to a constitutional defect.

The useful clinical move is to get ahead of the substitution rather than to explain the statute. Ask Missouri patients whether they use a hemp THC product, and if so, what it is, how much they take, by what route, how often, and what it does for them. Write the numbers down while the product is still available and the label is still in the house.

Pay particular attention to people using a low-dose beverage in place of alcohol. That group has the most to lose from an abrupt removal and the least likelihood of describing themselves as cannabis users, so the exposure will not appear on an intake form that asks about marijuana.

For patients whose use is genuinely therapeutic, Missouri has a licensed medical and adult-use system that is unaffected by this law. Moving a patient into a regulated channel before their product disappears is a better plan than letting them find a mail-order substitute in December. Dispensary products are generally more concentrated than a two to five milligram seltzer, so that transition needs a dose conversation, not just a referral.

The legal description here rests on primary material: the Governor’s signing announcement, the Missouri House summary of the truly agreed and finally passed bill, the federal statutory timeline, and the federal court docket. Those establish what the law says, when it was signed, what the conditional clause provides, and where the case stands.

The reading of how the conditional clause interacts with the revised federal schedule is an inference from those texts rather than a state agency determination. It is the reading the language supports and the one Missouri coverage has reflected, but no Missouri regulator has published a product-by-product interpretation, and a court could read the clause differently. Anyone making a business or compliance decision needs counsel, not a clinical article.

Much of the public discussion of this law has come through industry groups and the businesses suing over it. Their description of the harm is a party’s position in active litigation, and the state’s position is that the statute is clear enough to follow. Both are advocacy until a judge rules.

The claim that Missouri shelves will empty on a specific day should be treated carefully in either direction. Enforcement posture, inventory decisions, and any ruling in the pending case can all change what actually happens, and predictions about a retail market are not the same class of statement as a citation to a statute.

None of this establishes that hemp THC beverages are safe, effective, or a reasonable substitute for alcohol. A legislature restricting a product is not evidence that it is harmful, and a court declining to stop the restriction is not evidence either. The clinical questions about low-dose oral THC are open and are not answered by a state ban.

Nothing here shows what happens to the people who lose access. No Missouri data describe where displaced buyers go, whether pediatric exposures fall, whether alcohol consumption rises, or whether emergency visits change. Those outcomes are the ones that would tell anyone whether the policy worked, and they have not been measured.

Missouri wrote a state law whose reach floats with a federal date, then Congress moved part of that date by a month in an appropriations bill. That is a design problem several states now share, and it is worth naming because it produces exactly the uncertainty that the plaintiffs in this case are complaining about, without any regulator intending it.

It also points at something clinicians see repeatedly. Cannabinoid policy is made through definitions, and the definitions are drafted faster than the market can adapt to them. A patient’s product does not change when the definition changes. Only its legality does, and the two get confused constantly in the exam room.

I have spent years telling patients that legality and safety are different questions, and Missouri is about to run that lesson at scale. The seltzer somebody has been drinking instead of two beers is not going to become dangerous in November. It is going to become unavailable, and those are not the same thing.

The group I would worry about is the one that does not think of itself as using cannabis at all. A low-dose THC beverage replaced alcohol for a lot of people quietly and successfully. If that option disappears without a conversation, some of them go back to drinking, and that is a worse outcome than anything this law is trying to prevent.

So my advice to Missouri colleagues is to ask now, in September, while the products are still on the shelf and the label is still in the fridge. Write down the milligrams. If you wait until the change happens, you will be reconstructing a dose history from memory, and you will be doing it after the substitution has already gone wrong.

Missouri’s HB 2641 restrictions were written to begin November 12, 2026, but the statute ties its reach to the period in which federal restrictions prohibit the covered products, and the act signed on September 2 moved most of the federal schedule to December 11 while leaving one category on November 12. The lawsuit challenging the law’s clarity is pending and no injunction has issued. Clinicians should document what Missouri patients are using now rather than waiting to learn which date applied to them.

Take away three things: the Missouri law is signed and not in doubt, its start date now depends on which federal category a product falls into, and the case challenging it has not been decided. Do not take away that the products involved were shown to be harmful, or that anything on a Missouri shelf today is clinically appropriate for a given person.